In a recent video interview, Nina Kottler, MD, discussed the promise of artificial intelligence (AI) for improving workflow efficiency for radiologists, keys to assessing AI vendors and change management principles for facilitating implementation of AI into one’s practice.
There is fair amount of excitement and hype about the ongoing emergence of artificial intelligence (AI) and the potential promise of the technology in improving diagnostic accuracy and increasing workflow efficiencies in radiology.
However, as Nina Kottler, MD, points out in a recent video interview with Diagnostic Imaging, there are challenges as well when it comes to assessment and implementation of AI into one’s practice. While there are “hundreds of FDA-cleared and approved algorithms in radiology alone,” she notes that it is “early on in the maturity of the technology of AI with respect to health care” so choosing the right AI vendor for your practice is critical.
While technical prowess is important, 80 percent of what an AI vendor does is help create the workflow around the algorithm to ensure it works well, according to Dr. Kottler, the Associate Chief Medical Officer for Clinical AI and VP of Clinical Operations at Radiology Partners. Dr. Kottler says cultural alignment is an important consideration as you are seeking a vendor that values your input as a radiologist and is on a similar wavelength with you on future directions of AI in radiology.
For pertinent insights on the assessment and implementation of AI technology, watch the video below.
The Reading Room Podcast: Emerging Trends in the Radiology Workforce
February 11th 2022Richard Duszak, MD, and Mina Makary, MD, discuss a number of issues, ranging from demographic trends and NPRPs to physician burnout and medical student recruitment, that figure to impact the radiology workforce now and in the near future.
AI Mammography Platform Shows Promising Results for Detecting Subclinical Breast Cancer
October 3rd 2024Mean artificial intelligence (AI) scoring for breasts developing cancer was double that of contralateral breasts at initial biennial screening and was 16 times higher at the third biennial screening, according to a study involving over 116,000 women with no prior history of breast cancer.